mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 501–600 of 1,062
Perspectives for therapy of treatment‐resistant depression
Papp, M., Cubała, W. J., Święcicki, Ł., Newman‐Tancredi, A., & Willner, P. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15596 · Cited by 104
“(Li et al., 2010; Newman-Tancredi, Martel, et al., 2009; Reus et al., 2014), an effect that is important for its RAAD properties.”
BackgroundArg Kinase Regulates Prefrontal Dendritic Spine Refinement and Cocaine-Induced Plasticity
Gourley, S. L., Olevska, A., Warren, M. S., Taylor, J. R., & Koleske, A. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2730-11.2012 · Cited by 98
“Dendritic spine densities in adult layer V oPFC here were comparable with those determined following Lucifer yellow or biocytin loading (Liu and Aghajanian, 2008; Chen et al., 2009; Li et al., 2010), or by electron microscopy (Kuroda et al.”
ResultDevelopments in the field of antidepressants, where do we go now?
Artigas, F. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.04.013 · Cited by 104
“Cellular/molecular studies have revealed that ketamine increases the formation of new synapses through a mTOR-dependent mechanism (Li et al., 2010), suggesting that its antidepressant actions are mediated by a remodelling of brain networks involved in antidepressant action.”
BackgroundBrain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review
Strous, J. F. M., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D. A. J. P., Lok, A., Schoevers, R. A., & Figee, M. (2022) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2022.795231 · Cited by 103
BDNF signaling is necessary for the antidepressant-like effect of naringenin
Yi, L., Liu, B., Li, J., Luo, L., Liu, Q., Geng, D., Tang, Y., Xia, Y. Z., & Wu, D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.002 · Cited by 103
“Our preliminary experiment showed that acute administration of naringenin did not change sucrose preference and first feeding latency in mice exposed to CUMS (data not shown), which were two measurement indices used to distinguish between rapid and traditional antidepressants (Li et al., 2010).”
Synaptic Mechanisms Regulating Mood State Transitions in Depression
Parekh, P. K., Johnson, S. B., & Liston, C. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-110920-040422 · Cited by 101
Gregorio, D. D., Inserra, A., Enns, J. P., Markopoulos, A., Pileggi, M., Rahimy, Y. E., López-Canul, M., Comai, S., & Gobbi, G. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01301-9 · Cited by 103
“Neurogenesis and synaptogenesis are evoked as plasticity mechanism underlying the mechanism of action of approved antidepressants [54, 55] and psychedelic compounds [27], attenuating the negative effects of stress and depression on hippocampal [56] and prefrontal cortex [57] plasticity.”
BackgroundZhang, D., Wang, X., & Lu, X.-Y. (2016) · Endocrinology · doi:10.1210/en.2015-2078 · Cited by 96
Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 105
In vivo evidence of lower synaptic vesicle density in schizophrenia
Radhakrishnan, R., Skosnik, P. D., Ranganathan, M., Naganawa, M., Toyonaga, T., Finnema, S., Hillmer, A. T., Esterlis, I., Huang, Y., Nabulsi, N., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01184-0 · Cited by 100
Amidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y.-K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 90
Jiang, B., Wang, Y., Wang, H., Song, L., Huang, C., Zhu, Q., Wu, F., & Zhang, W. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13668 · Cited by 96
“Other brain regions, especially the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), are also implicated in depression (Di Chiara et al., 1999; Li et al., 2010).”
BackgroundKetamine’s antidepressant effect is mediated by energy metabolism and antioxidant defense system
Weckmann, K., Deery, M. J., Howard, J. A., Feret, R., Asara, J. M., Dethloff, F., Filiou, M. D., Iannace, J., Labermaier, C., Maccarrone, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16183-x · Cited by 87
A Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
“The FST has been widely used to assess ketamine’s antidepressant action (Autry et al., 2011; Li et al., 2010; Maeng et al., 2008; Trullas and Skolnick, 1990; Zanos et al., 2016).”
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
“This AMPA activity appears to be critical, as rodent studies found that AMPA antagonists abolished ketamine’s behavioral, antidepressant, and mTORstimulating effects (Moghaddam et al., 1997; Maeng et al., 2008; Li et al., 2010).”
BackgroundWu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P., & Kozorovitskiy, Y. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.022 · Cited by 95
“We found that 2 days of stressful experience is suf fi cient to decrease the potential of spinogenesis in mPFC pyramidal neurons, in contrast to changes in dendritic spine density that normally manifest after chronic stress (16,63,64).”
BackgroundMechanisms underlying the antidepressant response and treatment resistance
Levinstein, M. R., & Samuels, B. A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00208 · Cited by 102
Modeling treatment-resistant depression
Samuels, B. A., Leonardo, E. D., Gadient, R., Williams, A., Zhou, J., David, D. J., Gardier, A. M., Wong, E. H. F., & Hen, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.017 · Cited by 87
“Interestingly, recent work has demonstrated that in rats ketamine rapidly activates the mTOR pathway, leading to increased synaptic signaling proteins and an increased number of functional new synapses in the prefrontal cortex (Li et al., 2010).”
InfluentialMouillet‐Richard, S., Baudry, A., Launay, J., & Kellermann, O. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.035 · Cited by 99
Common mechanisms of pain and depression: are antidepressants also analgesics?
Nekovářová, T., Yamamotová, A., Valeš, K., Stuchlík, A., Fricová, J., & Rokyta, R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00099 · Cited by 101
“Similarly, some studies point to the antidepressive effects of NMDA antagonists (Berman et al., 2000; Zarate et al., 2006; Li et al., 2010).”
Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder
Zhang, L., Zhou, W., Ji, Y.-J., Li, Y., Zhao, N., Chen, H., Xue, R., Mei, X.-G., Zhang, Y., Wang, H., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3697-9 · Cited by 99
“Ketamine decreased the immobility time in the forced swim test in rats (Engin et al. 2009; Garcia et al. 2008a, b; Li et al. 2010; Yilmaz et al. 2002) and mice (da Silva et al.”
BackgroundZhang, K., Xu, T., Yuan, Z., Wei, Z., Yamaki, V. N., Huang, M., Huganir, R. L., & Cai, X. (2016) · Science Signaling · doi:10.1126/scisignal.aai7884 · Cited by 98
Koike, H., Fukumoto, K., Iijima, M., & Chaki, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.023 · Cited by 99
The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis
Russo, E., Citraro, R., Constanti, A., & Sarro, G. D. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8314-5 · Cited by 98
Acute d-serine treatment produces antidepressant-like effects in rodents
Malkesman, O., Austin, D. R., Tragon, T., Wang, G., Rompala, G., Hamidi, A. B., Cui, Z., Young, W. S., Nakazawa, K., Zarate, C. A., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001386 · Cited by 92
“Preclinical studies have noted similar antidepressant effects associated with a single injection of ketamine or a NR2B antagonist (Li et al. 2010, 2011 ; Maeng et al. 2008b).”
BackgroundInfluentialRothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120970879 · Cited by 97
“…and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity, sustained default-mode network attenuation, and glutamate modulation (Duman et al., 2012; Li et al., 2010; Maeng et al., 2008; Scheidegger et al., 2012; Zanos et al., 2016).”
BackgroundHarvey, B. H., & Shahid, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.014 · Cited by 97
Ketamine: Neuroprotective or Neurotoxic?
Choudhury, D., Autry, A. E., Tolias, K. F., & Krishnan, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.672526 · Cited by 82
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 99
Clarke, M., Razmjou, S., Prowse, N. A., Dwyer, Z., Litteljohn, D., Pentz, R., Anisman, H., & Hayley, S. P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.021 · Cited by 97
Ketamine and other potential glutamate antidepressants
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.028 · Cited by 98
“Although differences in synaptic cascade have been noted (Li et al., 2010) there are changes in both NMDA and AMPA receptors with fluoxetine (Ampuero et al.”
BackgroundInfluentialFukumoto, K., Iijima, M., Funakoshi, T., & Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx116 · Cited by 90
“Indeed, ketamine has been reported to enhance synaptic protein synthesis and dendritic spine density in the mPFC (Li et al., 2010; Dong et al., 2017).”
BackgroundInfluentialLussier, A. L., Lebedeva, K., Fenton, E. Y., Guskjolen, A. J., Caruncho, H. J., & Kalynchuk, L. E. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.012 · Cited by 96
“We used the method of Li et al. (2010).”
Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation
Harraz, M. M., Tyagi, R., Cortés, P., & Snyder, S. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.211 · Cited by 95
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
“Activation of Akt following phosphorylation leads to enhanced activity of mTOR which is responsible for regulating the expression of several genes involved in cell growth, particularly a group of synapse-associated genes that have been directly linked to neuroplastic events [248].”
BackgroundDunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
Wilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.004 · Cited by 95
“Ketamine induces neuroplastic changes (increases in spine density, synaptic strengthening) over periods of hours to days following exposure in animals (5,46).”
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
Molecular network of neuronal autophagy in the pathophysiology and treatment of depression
Jia, J., & Le, W. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1548-2 · Cited by 96
“A rapid antidepressant and nonselective NMDAR antagonist, ketamine, activates the mTOR signaling pathway, leading to increased synaptic proteins in the rat prefrontal cortex([73]).”
BackgroundZinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity
Doboszewska, U., Wlaź, P., Nowak, G., Radziwoń-Zaleska, M., Cui, R., & Młyniec, K. (2017) · Neural Plasticity · doi:10.1155/2017/3682752 · Cited by 88
“, postsynaptic density protein 95 (PSD95), synapsin I or GluA1) and an increased number and function of new synapses in the prefrontal cortex of rats [158].”
InfluentialOta, K. T., & Duman, R. S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.022 · Cited by 94
Self-citationBonnet, U. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1072653 · Cited by 90
“…and biochemical response is observed within a narrow range (1-∼30 mg/kg intraperitoneal injection)—at higher, yet anaesthetic doses, ketamine’s antidepressant efficacy is lost, resulting in an inverted U/parabolic dose-response curve (Li et al. 2010; Autry et al. 2011; Chowdhury et al. 2012).”
BackgroundZurek, A. A., Bridgwater, E. M., & Orser, B. A. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31824720da · Cited by 94
“which increases synaptic signaling proteins and the number and function of synapses in the cortex.(37) Modulation of 5GABAA receptors by isoflurane plays a crucial role in initiating the memory deficits that were evident”
BackgroundDuncan, W. C., Slonena, E., Hejazi, N. S., Brutsche, N., Yu, K. C., Park, L., Ballard, E. D., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.011 · Cited by 93
“Changes in glutamatergic transmission affect downstream struct ural changes in dendritic spines and local synaptic protein synthesis (6), including transport and release of brain-derived neurotrophic factor (BDNF) (7).”
Jiang, B., Wang, H., Wang, J., Wang, Y., Zhu, Q., Wang, C., Song, L., Gao, T., Wang, Y., Meng, G., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.10.004 · Cited by 93
The anterior cingulate cortex as a key locus of ketamine’s antidepressant action
Alexander, L., Jelen, L. A., Mehta, M. A., & Young, A. H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.003 · Cited by 78
“Such rapid effects cannot be due to synaptogenesis which takes at least several hours to occur (Li et al., 2010).”
State-Dependent Partial Occlusion of Cortical LTP-Like Plasticity in Major Depression
Kühn, M., Mainberger, F., Feige, B., Maier, J. G., Mall, V., Jung, N. H., Reis, J., Klöppel, S., Normann, C., & Nissen, C. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.310 · Cited by 93
Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder
Machado-Vieira, R., Zanetti, M. V., Teixeira, A. L., Uno, M., Valiengo, L. L., Soeiro-de-Souza, M. G., Oba-Shinjo, S. M., de Sousa, R. T., Zarate, C. A., Gattaz, W. F., et al. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.02.002 · Cited by 84
“Please cite this article as: Machado-Vieira, R., et al., Decreased AKT1 European Neuropsychopharmacology (2015), http://dx.”
BackgroundCircadian regulation of mammalian target of rapamycin signaling in the mouse suprachiasmatic nucleus
Cao, R., Anderson, F. E., Jung, Y.-J., Dziema, H., & Obrietan, K. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.005 · Cited by 87
“…work showing that mTOR affects neuronal structure and synaptic communication (Tang et al., 2002; Cammalleri et al., 2003; Buckmaster et al., 2009; Li et al., 2010) it may be worthwhile examining whether mTOR influences the rhythmic reorganization of SCN neuronal networks, which is observed…”
BackgroundSun, H.-L., Zhou, Z.-Q., Zhang, G.-F., Yang, C., Wang, X.-M., Shen, J.-C., Hashimoto, K., & Yang, J.-J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.21 · Cited by 84
Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice
Liu, Y., Niu, L., Wang, L., Bai, L., Fang, X., Li, Y., & Yi, L. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.08.008 · Cited by 93
Neuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
“target of rapamycin (mTOR)-dependent synapse formation underlies ketamine's rapid antidepressant properties (Li et al., 2010).”
BackgroundInfluentialJett, J. D., Bulin, S. E., Hatherall, L. C., McCartney, C. M., & Morilak, D. A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.01.017 · Cited by 92
“Acute ketamine administration increases glutamate signaling through AMPA receptors in the mPFC, which is necessary for its therapeutic-like effects after chronic stress (Moghaddam et al., 1997; Li et al., 2010).”
BackgroundDisorders of memory and plasticity in psychiatric disease
Pittenger, C. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.4/cpittenger · Cited by 92
“At these doses, ketamine produces a rapid and substantial increase in glutamate in the frontal cortex and induces morphological and electrophysiological synaptogenesis in the frontal cortex.(55) This apparently direct connection engenders optimism that other treatments—focused directly on the enhancement of plasticity…”
BackgroundLudka, F. K., Zomkowski, A. D. E., Cunha, M. P., Dal-Cim, T., Zeni, A. L. B., Rodrigues, A. L. S., & Tasca, C. I. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.005 · Cited by 92
The Role of Chronic Stress in Anxious Depression
Ross, R. A., Foster, S. L., & Ionescu, D. F. (2017) · Chronic Stress · doi:10.1177/2470547016689472 · Cited by 92
“N-methyl-D-aspartate receptors play a significant role in synaptic strength and plasticity, and ketamine has been shown in rodent models to increase the density of synaptic dendritic spines.(65) Intriguingly, it is this activity that is likely responsible for the antidepressant quality; administration of ketamine in a…”
BackgroundLiu, S., Li, T., Liu, H., Wang, X., Bo, S., Xie, Y., Bai, X., Wu, L., Wang, Z., & Liu, D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.037 · Cited by 92
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Huang, Y.-J., Lin, C.-H., Lane, H.-Y., & E. Tsaid, G. (2012) · Current Neuropharmacology · doi:10.2174/157015912803217288 · Cited by 85
“…NSC-101-2325-B-039-009, NSC 101-2314- B-182A-073-MY2), National Health Research Institutes, Taiwan (NHRI-EX-101-9904NI), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH101-TD-B-111-004), and China Medical University Hospital, Taiwan (DMR-99-120 and DMR-100-161).”
Guo, M., Lu, Y., Garza, J. C., Li, Y., Chua, S. C., Zhang, W., Lu, B., & Lu, X.-Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.9 · Cited by 83
The PSD-95/nNOS complex: New drugs for depression?
Doucet, M. V., Harkin, A., & Dev, K. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.005 · Cited by 96
“…the expression of synaptic proteins and the density of dendritic spines in tandem with a rapid antidepressant response in behavioural tests (Li et al., 2010, Li et al., 2011). mTOR is a serine/threonine kinase that has been implicated in activity-dependent synaptic plasticity and controls…”
BackgroundKetamine-Associated Brain Changes: A Review of the Neuroimaging Literature
Ionescu, D. F., Felicione, J. M., Gosai, A., Cusin, C., Shin, P., Shapero, B. G., & Deckersbach, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000179 · Cited by 91
“This is of interest because rapidly induced synaptogenesis has been shown in preclinical models in response to ketamine.(6) Thus, here we review current human neuroimaging literature as it pertains to ketamine’s mechanism of action in specific brain areas, with an emphasis on key regions that are implicated in the pat…”
Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91
“Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild stress model and social defeat stress model (Li et al. 2010; Ma et al. 2013; Yang et al. 2015b; Zhang et al. 2015b).”
BackgroundStrasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., et al. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12497 · Cited by 84
“Ro 25-6981 ((aR,bS)-a-(4-hydroxyphenyl)b-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate), an antagonist of an NMDA receptor subtype (GluN2B),(31) was shown to produce rapid (within 24 h) antidepressant effects in rats.(32) MK0657 (CERC-301), an orally bioavailable NMDA receptor 2B subtype antagonist (NR2B),(33)…”
BackgroundShamay-Ramot, A., Khermesh, K., Porath, H. T., Barak, M., Pinto, Y., Wachtel, C., Zilberberg, A., Lerer-Goldshtein, T., Efroni, S., Levanon, E. Y., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005702 · Cited by 85
“Taking into account the role of mTor in regulating structural, synaptic plasticity [30], it may play a role in the mechanism that regulates the assembly of neuronal circuits that regulate behavior in zebrafish and FXS.”
BackgroundCoplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2
Lopez, J. P., Lücken, M. D., Brivio, E., Karamihalev, S., Kos, A., De Donno, C., Benjamin, A., Yang, H., Dick, A. L. W., Stoffel, R., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.05.001 · Cited by 79
“This is in line with ketamine’s inverted U-shaped dose response (Li et al., 2010).”
Stratinaki, M., Varidaki, A., Mitsi, V., Ghose, S., Magida, J., Dias, C., Russo, S. J., Vialou, V., Caldarone, B. J., Tamminga, C. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214696110 · Cited by 81
Pochwat, B., Szewczyk, B., Sowa-Kucma, M., Siwek, A., Doboszewska, U., Piekoszewski, W., Gruca, P., Papp, M., & Nowak, G. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001089 · Cited by 82
“4(a), CMS or magnesium treatment do not affect the level of the GluN2A subunit in the PFC. Two-way ANOVA demonstrated no significant effect of stress (F1, 28=0.16, p=0.9325), no significant effect of magnesium (F1,28=0.14, p=0.7129) and significant interaction (F1,28=4.40, p=0.0450).”
BackgroundInfluentialSynaptic plasticity model of therapeutic sleep deprivation in major depression
Wolf, E., Kühn, M., Normann, C., Mainberger, F., Maier, J. G., Maywald, S., Bredl, A., Klöppel, S., Biber, K. P. H., van Calker, D., et al. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.11.003 · Cited by 90
Ghosal, S., Duman, C. H., Liu, R.-J., Wu, M., Terwilliger, R., Girgenti, M. J., Wohleb, E., Fogaca, M. V., Teichman, E. M., Hare, B., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104669 · Cited by 89
Self-citationZhang, Z., Wang, W., Zhong, P., Liu, S. J., Long, J. Z., Zhao, L., Gao, H., Cravatt, B. F., & Liu, Q. (2015) · Hippocampus · doi:10.1002/hipo.22344 · Cited by 89
“mTOR-dependent protein synthesis and synaptogenesis might mediate the rapid antidepressantlike behavioral effects of NMDA receptor antagonists including ketamine (Li et al., 2010).”
BackgroundArabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89
Krystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 91
Quan, M., Zhang, N., Wang, Y.-Y., Zhang, T., & Yang, Z. R. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.026 · Cited by 92
Amat, J., Dolzani, S. D., Tilden, S., Christianson, J. P., Kubala, K. H., Bartholomay, K., Sperr, K., Ciancio, N., Watkins, L. R., & Maier, S. F. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3114-15.2016 · Cited by 79
“Ketamine (10 mg/kg, i.p.; Li et al., 2010) was administered 2 weeks, 1 week, or 2 h before IS, and anxiety was evaluated by the JSI test 24 h after the stressor.”
BackgroundMethodBDNF Release and Signaling Are Required for the Antidepressant Actions of GLYX-13
Kato, T., Fogaça, M. V., Deyama, S., Li, X.-Y., Fukumoto, K., & Duman, R. S. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.220 · Cited by 88
“Discussion The results demonstrate that the antidepressant actions of GLYX-13 are mediated by neuronal activation of VDCCs, activity dependent release of BDNF, and stimulation of TrkB signaling, notably new evidence for activation of Rac1 (see Supplementary Fig.”
BackgroundSelf-citationSestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126859 · Cited by 88
Self-citationInvestigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives
Karthik, S., Sharma, L. P., & Narayanaswamy, J. C. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s211703 · Cited by 130
Bettio, L. E. B., Cunha, M. P., Budni, J., Pazini, F. L., Oliveira‐Giacomelli, Á., Colla, A. R. D. S., & Rodrigues, A. L. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.06.021 · Cited by 89
Warren, B. L., Iniguez, S. D., Alcantara, L. F., Wright, K. N., Parise, E. M., Weakley, S. K., & Bolanos-Guzman, C. A. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1470-11.2011 · Cited by 81
Ketamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Fan, W., Yang, H., Sun, Y., Zhang, J., Li, G., Zheng, Y., & Liu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.13743 · Cited by 87
“Preclinical evidence indicates that mammalian target of rapamycin signaling [21], protein synthesis through eukaryotic translation elongation factor 2 dephosphorylation [22], as well as brain-derived neurotrophic factor increases [22, 23], underlie the rapid antidepressant responses of ketamine.”
BackgroundMoretti, M., Budni, J., Freitas, A. E., da Rosa, P. B., & Rodrigues, A. L. S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.10.014 · Cited by 88
Lara, D. R., Bisol, L. W., Brunstein, M. G., Reppold, C. T., de Carvalho, H. W., & Ottoni, G. L. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.036 · Cited by 87
“while they are present and also long-term effects due to rapidly induced structural changes in the brain (Li et al., 2010; Vollenweider and Kometer, 2010).”
BackgroundmTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86
“This latter effect leads to synaptogenesis in the prefrontal cortex of rat [62, 63].”
BackgroundChen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.033 · Cited by 86
The Effects of General Anesthetics on Synaptic Transmission
Hao, X., Ou, M., Zhang, D., Zhao, W., Yang, Y., Liu, J., Yang, H., Zhu, T., Li, Y., & Zhou, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200227125854 · Cited by 86
Zhan, Y., Zhou, Y., Zheng, W., Liu, W., Wang, C., Lan, X., Deng, X., Xu, Y., Zhang, B., & Ning, Y. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00933-z · Cited by 81
Perrine, S. A., Ghoddoussi, F., Michaels, M. S., Sheikh, I. S., McKelvey, G. M., & Galloway, M. P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.003 · Cited by 89
Duric, V., & Duman, R. S. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1020-7 · Cited by 79
“Selective inhibition of AMPA receptor function completely blocked ketamine-mediated induction of mTOR signaling, as well as activation of its upstream activators (Akt and ERK) and downstream target proteins (p70S6 and 4E-BP1) [158].”
BackgroundInfluentialSelf-citationRéus, G. Z., Carlessi, A. S., Titus, S. E., Abelaira, H. M., Ignácio, Z. M., da Luz, J. R., Matias, B. I., Bruchchen, L., Florentino, D., Vieira, A., et al. (2015) · Developmental Neurobiology · doi:10.1002/dneu.22283 · Cited by 81
“With regards to the mechanism of action by which ketamine exerts antidepressant effects, it is known that brain derived neurotrophic factor (BDNF), mammalian target of rapamycin (mTOR) and MAPK kinase signaling pathways, as well as the a-Amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) are important…”
BackgroundDakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.005 · Cited by 85
“Its anti-depressant activity has been linked to the enduring promotion of neural plasticity in prefrontal regions (Li et al., 2010), perhaps influenced by a metabolite with a relatively long half-life (Zanos et al.”
IQGAP1 regulates NR2A signaling, spine density, and cognitive processes
Gao, C., Frausto, S. F., Guedea, A. L., Tronson, N. C., Jovasevic, V., Leaderbrand, K., Corcoran, K. A., Guzman, Y. F., Swanson, G. T., & Radulovic, J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1300-11.2011 · Cited by 85
“Alternatively, spine density may be specifically involved in the regulation of mnemonic rather than emotional and motivational processes, and changes seen in mood disorders (Li et al., 2010) could be related to the cognitive deficits accompanying these illnesses.”
BackgroundKetamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions
Salvadore, G., & Singh, J. B. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12103 · Cited by 81
“[33], who showed activation of the mTOR complex and key components of translation initiation, p70 ribosomal S6 kinase (p70S6K) and eIF4E-binding after administration of subanesthetic ketamine (10 mg/kg).”
BackgroundCahill, M. E., Bagot, R. C., Gancarz, A. M., Walker, D. M., Sun, H., Wang, Z.-J., Heller, E. A., Feng, J., Kennedy, P. J., Koo, J. W., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.031 · Cited by 80
“In some studies, upregulation of PSD-95 in response to mTOR activation is associated with spine maturation (Li et al., 2010), while other studies have shown that upregulation of Arc, an established facilitator of thin spine formation (Peebles et al.”
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
Kryst, J., Kawalec, P., & Pilc, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1683161 · Cited by 77
Cell-type specific modulation of NMDA receptors triggers antidepressant actions
Pothula, S., Kato, T., Liu, R.-J., Wu, M., Gerhard, D., Shinohara, R., Sliby, A.-N., Chowdhury, G. M. I., Behar, K. L., Sanacora, G., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0796-3 · Cited by 81
“We target GluN2B, one of the major NMDAR subunits expressed on both inhibitory and excitatory neurons in mPFC, as preclinical and clinical studies have reported that selective GluN2B antagonists produce rapid antidepressant effects [11, 18].”
BackgroundSelf-citationRahimian, R., Belliveau, C., Chen, R., & Mechawar, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871997 · Cited by 88
“Several investigations have reported decreased brain mTOR activation in animal models of depression (267).”
BackgroundStructural neural plasticity evoked by rapid-acting antidepressant interventions
Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. M., & Kwan, A. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00876-0 · Cited by 87
“Preclinical studies have shown that dendritic spines in cortical neurons are targeted for remodelling by ketamine 68 , classic psychedelics (for example, psilocybin and 5-MeO-DMT) 69,70 , ECT 71 and repetitive TMS 72,73 .”
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.